Recommended studies to perform at diagnosis for patients with CLL to identify high-risk patients
. | Clinical practice* . | Clinical trials† . |
|---|---|---|
| Staging (Rai or Binet) | Yes | Yes |
| Lymphocyte doubling time | Yes | Yes |
| β-2 Microglobulin | Yes | Yes |
| Cytogenetics by FISH | Yes | Yes |
| CD38 status | Yes | Yes |
| IgVh mutation status | If available | Yes |
| ZAP-70 | Not available | Yes |
| Thymidine kinase | No | Consider |
| Markers of angiogenesis‡ | No | Consider |
| Statistical modeling | Not available | Yes |
. | Clinical practice* . | Clinical trials† . |
|---|---|---|
| Staging (Rai or Binet) | Yes | Yes |
| Lymphocyte doubling time | Yes | Yes |
| β-2 Microglobulin | Yes | Yes |
| Cytogenetics by FISH | Yes | Yes |
| CD38 status | Yes | Yes |
| IgVh mutation status | If available | Yes |
| ZAP-70 | Not available | Yes |
| Thymidine kinase | No | Consider |
| Markers of angiogenesis‡ | No | Consider |
| Statistical modeling | Not available | Yes |
Recommendations for clinicians in “routine” evaluation of their patients with CLL.
Recommendations for risk stratification parameters that should be measured in clinical trials in which formal biostatistical analysis can be performed on well-characterized groups of patients with CLL.
Including both marrow angiogenesis levels as well as serum levels of proangiogenic and antiangiogenic factors.